In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia (original) (raw)
Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cells
Andrew J Massey
Molecular Cancer, 2014
View PDFchevron_right
Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1
Stephan Grant
Molecular Cancer Therapeutics, 2008
View PDFchevron_right
Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies
Ian Collins
Expert opinion on drug discovery, 2013
View PDFchevron_right
Characterization of novel Checkpoint kinase 1 inhibitors by in vitro assays and in human cancer cells treated with topoisomerase inhibitors
Gilles Ferry
Life Sciences, 2011
View PDFchevron_right
Evaluation of checkpoint kinase targeting therapy in Acute Myeloid Leukemia with complex karyotype
Christine Didier
Cancer Biology & Therapy, 2012
View PDFchevron_right
Context-Dependent Cell Cycle Checkpoint Abrogation by a Novel Kinase Inhibitor
Andrew J Massey
PLoS ONE, 2010
View PDFchevron_right
Transient knock down of checkpoint kinase 1 in hematopoietic progenitors is linked to bone marrow toxicity
Bart Jessen
Toxicology Letters, 2011
View PDFchevron_right
Effects of Selective Checkpoint Kinase 1 Inhibition on Cytarabine Cytotoxicity in Acute Myelogenous Leukemia Cells In Vitro
Judith Karp
Clinical Cancer Research, 2012
View PDFchevron_right
11 Cellular Inhibition of Checkpoint Kinase 2
Gabriele Zoppoli
View PDFchevron_right
Targeting checkpoint kinase 1 in cancer therapeutics
Richard Carvajal
Clinical Cancer Research, 2007
View PDFchevron_right
Checkpoint kinase 1 protein expression indicates sensitization to therapy by checkpoint kinase 1 inhibition in non–small cell lung cancer
Dafydd Thomas
Journal of Surgical Research, 2014
View PDFchevron_right
Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor
Andrew Jobson
Protein Science, 2008
View PDFchevron_right
Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias
tomoko freshwater
Clinical Cancer Research, 2012
View PDFchevron_right
Cellular Inhibition of Checkpoint Kinase 2 (Chk2) and Potentiation of Camptothecins and Radiation by the Novel Chk2 Inhibitor PV1019 [7-Nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]
Andrew Jobson
Journal of Pharmacology and Experimental Therapeutics, 2009
View PDFchevron_right
Evaluation of Polo-like Kinase 1 inhibition on the G2/M checkpoint in Acute Myelocytic Leukaemia
Christine Didier
European Journal of Pharmacology, 2008
View PDFchevron_right
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia
Anna Ferrari
Oncotarget, 2016
View PDFchevron_right
Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2
Michelle Garrett
Bioorganic & Medicinal Chemistry, 2010
View PDFchevron_right
Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response
Alaa Alshareeda
British Journal of Cancer, 2015
View PDFchevron_right
PF00477736 Mediates Checkpoint Kinase 1 Signaling Pathway and Potentiates Docetaxel-Induced Efficacy in Xenografts
Cory Zhang
Clinical Cancer Research, 2009
View PDFchevron_right
Discovery of 4′-(1,4-dihydro-indeno[1,2- c]pyrazol-3-yl)-benzonitriles and 4′-(1,4-dihydro-indeno[1,2- c]pyrazol-3-yl)-pyridine-2′-carbonitriles as potent checkpoint kinase 1 (Chk1) inhibitors
Ha Bui
Bioorganic & Medicinal Chemistry Letters, 2007
View PDFchevron_right
Part III: Novel checkpoint kinase 2 (Chk2) inhibitors; design, synthesis and biological evaluation of pyrimidine-benzimidazole conjugates
Yasmin Mohamed Attia
European journal of medicinal chemistry, 2018
View PDFchevron_right
Substrate specificity determinants of the checkpoint protein kinase Chk1
James Hutchins
FEBS letters, 2000
View PDFchevron_right
Mutation analysis of the DNA-damage checkpoint gene CHK2 in myelodysplastic syndromes and acute myeloid leukemias
Sigal Tavor
Leukemia Research, 2001
View PDFchevron_right
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies
Graeme Walker
Molecular Cancer Therapeutics, 2008
View PDFchevron_right
The Novel Chk1 Inhibitor MK-8776 Sensitizes Human Leukemia Cells to HDAC Inhibitors by Targeting the Intra-S Checkpoint and DNA Replication and Repair
Maciej Kmieciak
Molecular Cancer Therapeutics, 2013
View PDFchevron_right
Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints
Andrew Burgess
2003
View PDFchevron_right
A phospho-proteomic screen identifies substrates of the checkpoint kinase Chk1
Josep Forment
Genome Biology, 2011
View PDFchevron_right
Structure activity and structure property relationships of a novel series of potent inhibitors of Checkpoint kinases
Patrick Brassil
2007
View PDFchevron_right
Structural characterization of inhibitor complexes with checkpoint kinase 2 (Chk2), a drug target for cancer therapy
Andrew Jobson
Journal of Structural Biology, 2011
View PDFchevron_right
The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe
David Horne
Oncogene, 2004
View PDFchevron_right
Identification of Inhibitors of Checkpoint Kinase 1 through Template Screening
Sam Peacock
Journal of Medicinal Chemistry, 2009
View PDFchevron_right